Sunday, October 24

08:00 – 08:15 Davos 2

Welcome Address by the Senior Programme directors and the President of the Swiss Society of Cardiology

08:15 – 09:45 Davos 2

Session 1: Atherosclerosis and Lipid Management

Chair: Augusto Gallino, Bellinzona / John Deanfield, London

The changing landscape of atherosclerosis

Peter Libby, Boston

Novel antilipidaemic drugs: PCSK9 inhibitors and bempedoic acid

François Mach, Geneva

Managing triglycerlides and Lp(a) in the context of residual risk

Ulrich Laufs, Leipzig

Genetic tools to treat dyslipidaemia: Pharmacotherapy of the future

Ulf Landmesser, Berlin

Panel discussion

09:45 – 10:15


10:15 – 11:45 Davos 2

Session 2: Risk Factors and Prevention

Chair: Christian Müller, Basel / François Mach, Geneva

Lifetime risk of cardiovascular disease: the new target

John Deanfield, London

Impact of air pollution and climate change on CVD and mortality

Salim Yusuf, Hamilton

The new 2021 Prevention ESC Guidelines

Frank Visseren, Utrecht

How much exercise is enough? The 2020 ESC Guidelines recommendations

Sanjay Sharma, London

Panel discussion

12:00 – 13:15 Davos 2

Lunch / Industry sponsored symposium

13:30 – 15:00 Davos 2

Session 3: Diabetes and Hypertension

Chair: Jürg H. Beer, Baden / Georg Ehret, Geneva

Debate: Is blood glucose the primary target in T2DM?

  • Naveed Sattar, Glasgow: yes!
  • Francesco Cosentino, Stockholm: No!
  • Rebuttals
Francesco Cosentino / Naveed Sattar

The polypill in primary prevention: A major global step forward

Salim Yusuf, Hamilton

Diabetic nephropathy, the FIGARO and FIDELIO Trials

Bertram Pitt, Ann Arbor

Hypertension management 2021: Targets, drugs and devices

Felix Mahfoud, Homburg/Saar

Panel discussion

15:00 – 15:30

Coffee / Poster Session

15:30 – 16:30

Parallel Sessions

a) Poster Session


Moderators: Giovanni G. Camici, Zurich and Bettina Heidecker, Berlin

b) Meet the Expert Session: How to implement prevention: Heart Age and beyond


Moderators and cases: John Deanfield, London and Ulf Landmesser, Berlin

John Deanfield, London / Ulf Landmesser, Berlin

c) Meet the Expert Session: Personalizing Lipid-lowering

Davos 2

Moderators and cases: Ulrich Laufs, Leipzig, François Mach, Geneva and Isabella Sudano, Zurich

Ulrich Laufs, Leipzig / François Mach, Geneva / I. Sudano

d) Meet the Expert Session: Cardio-Oncology: Managing Cardiac Patients

Davos 1

(Case based presentations)

15:30 How to assess cardiac function in cancer patients (Jereon J. Bax, Leiden)
15:45 Which chemotherapeutics do we have to consider? (Thomas Suter, Bern)
16:00 Cardiological monitoring of cancer patients (Teresa Lopez Fernandez, Madrid)
16:15 Panel discussion

Jeroen J. Bax, Leiden / Teresa Lopez Fernandez / Thomas Suter
16:30 – 17:30

Parallel Sessions

a) Cardio-Oncology / ACHD

Davos 2

Chair: Bernard Gersh, Rochester / Marc A. Pfeffer, Boston

  • Cardio-oncology – a new cardiovascular specialty?
    Teresa Lopez Fernandez, Madrid
  • Checkpoint inhibitors and cardiotoxicity
    Thomas Suter, Bern
  • Adult Congenital Heart Disease: What should the general cardiologist know?
    Michael Gatzoulis, London
  • Panel discussion
Teresa Lopez Fernandez / Michael Gatzoulis / Thomas Suter

b) Cardiac Imaging

Davos 1

Chair: Jeroen J. Bax, Leiden / Michel Zuber, Othmarsingen

  • Is ejection fraction reflecting myocardial performance?
    Victoria Delgado, Leiden
  • CT update: from structure to function
    Christoph Gräni, Berne
  • Coronary inflammation in CT
    Charalambos Antoniades, Oxford
  • Panel discussion
Victoria Delgado / Christoph Gräni / Charalambos Antoniades
17:30 – 18:15 Davos 2

Paul Lichtlen Lecture

Artificial intelligence in cardiology: present and future

Paul Friedman, Rochester MN
18:15 – 19:15 Exhibitor Area

Welcome Reception

19:15 – 20:15 Davos 1

Clinical Decision Seminar: Difficult ECG Interpretations

Moderators and cases: Firat Duru, Zurich / Christian Sticherling, Basel

Accreditation by Swiss Society for Endocrinology and Diabetology